Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

The Lancet

Volumn 375, Issue 9729, 2010, Pages 1875-1884

  Jun, Min ^a   Foote, Celine ^a   Lv, Jicheng ^a,b   Neal, Bruce ^a   Patel, Anushka ^a   Nicholls, Stephen J ^c   Grobbee, Diederick E ^d   Cass, Alan ^a   Chalmers, John ^a   Perkovic, Vlado ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PLACEBO;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; EMBASE; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 77952708442     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60656-3     Document Type: Article

References (46)

1. Murray C.J., and Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349 (1997) 1269-1276
2. Packard C. Improving outcomes through statin therapy-a review of ongoing trials. Eur Heart J 6 suppl A (2004) A28-A31
3. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
4. Gordon T., Kannel W.B., Castelli W.P., and Dawber T.R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 141 (1981) 1128-1131
5. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
6. Acheson J., and Hutchinson E.C. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 15 (1972) 177-183
7. The Coronary Drug Project Research Group. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220 (1972) 996-1008
8. WHO Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40 (1978) 1069-1118
9. Birjmohun R.S., Hutten B.A., Kastelein J.J., et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
10. Alsheikh-Ali A.A., Kuvin J.T., Karas R.H., Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
11. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
12. Ginsberg H.N., Elam M.B., Lovato L.C., et al., for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010) 1563-1574
13. Jadad A.R., Carroll D., Moore A., and McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 66 (1996) 239-246
14. In: Woodward M. (Ed). Epidemiology: design and data analysis. 2nd edn. (2005), Chapman and Hall/CRC Press, Boca Raton
15. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
16. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
17. Rubins H.B., Robins S.J., Collins D., et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
18. Meade T., Zuhrie R., Cook C., et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 325 (2002) 1139
19. Arthur J.B., Raffle R.B., Ashby W.R., et al. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 4 (1971) 767-775
20. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. BMJ 4 (1971) 775-784
21. Emmerich K.H., Poritis N., Stelmane I., et al. Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy. Klin Monatsbl Augenheilkd 226 (2009) 561-567
22. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
23. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
24. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
25. The Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 4 (1973) 684-693
26. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
27. Lopid Coronary Angiography Trial (LOCAT) Study Group, Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96 (1997) 2137-2143
28. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21 (1998) 641-648
29. Nilsson J., Ericsson C.G., Hamsten A., Grip L., Svane B., and De Faire U. Bezafibrate following acute myocardial infarction: important findings from the Bezafibrate Coronary Atherosclerosis Intervention Trial. Fibrinolysis Proteolysis 11 suppl 1 (1997) 159-162
30. Hanefeld M., Fischer S., Schmechel H., et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14 (1991) 308-317
31. Meade T. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med 2 (2001) 195-204
32. Ansquer J.C., Foucher C., Rattier S., et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493
33. Keech A.C., Mitchell P., Summanen P.A., et al., for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
34. Duvall S., and Tweedie R. A nonparametric "trim and fill" method for assessing publication bias in meta-analysis. J Am Stat Assoc 95 (2000) 89-98
35. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32 (2009) 493-498
36. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
37. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
38. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
39. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
40. Drury P., Pardy C., Davis T., Zannino D., Laakso M., and Keech A. Reduced renal function (eGFR) and albuminuria in type 2 diabetes independently predict cardiovascular (CVD) events and mortality even in a low risk cohort: the FIELD Study. Circulation 118 (2008) S1088 (abstr).
41. Freyberger H., Schifferdecker E., and Schatz H. Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent. Medizinische Klinik 89 (1994) 594-597
42. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
43. Ruan X.Z., Moorhead J.F., Fernando R., et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14 (2003) 593-600
44. Barbier O., Torra I.P., Duguay Y., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 717-726
45. Nicholls S.J., Rye K.A., Barter P.J., Nicholls S.J., Rye K.-A., and Barter P.J. High-density lipoproteins as therapeutic targets. Curr Opin Lipidol 16 (2005) 345-349
46. Marx N., Kehrle B., Kohlhammer K., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 (2002) 703-710